Alleima AB (publ) (STO:ALLEI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 19.91B +12.6% |
| Revenue (ttm) | 18.06B -10.2% |
| Net Income | 567.00M -63.7% |
| EPS | 2.27 -63.6% |
| Shares Out | 250.16M |
| PE Ratio | 35.11 |
| Forward PE | 16.27 |
| Dividend | 2.50 (3.05%) |
| Ex-Dividend Date | Apr 30, 2026 |
| Volume | 144,270 |
| Average Volume | 417,886 |
| Open | 81.70 |
| Previous Close | 81.95 |
| Day's Range | 78.90 - 82.05 |
| 52-Week Range | 67.15 - 88.95 |
| Beta | 1.08 |
| RSI | 52.40 |
| Earnings Date | Apr 27, 2026 |
About Alleima AB
Alleima AB (publ) manufactures and sells stainless steels, special alloys, medical wires and components, and electric heating systems in Europe, North America, Asia, and internationally. It operates through three divisions: Tube, Kanthal, and Strip. The company offers tubes for extraction and production of oil and gas, advanced stainless steel, umbilical tubes, control lines, corrosion-resistant alloys, and oil country tubular goods; solid and hollow bar, high-pressure and composite tubing, semi-finished ingots and blooms, and billets; hydrauli... [Read more]
Financial Performance
In 2025, Alleima AB's revenue was 18.63 billion, a decrease of -5.39% compared to the previous year's 19.69 billion. Earnings were 671.00 million, a decrease of -45.05%.
Financial StatementsNews
Alleima AB (SAMHF) Q1 2026 Earnings Call Highlights: Navigating Market Challenges with ...
Alleima AB (SAMHF) Q1 2026 Earnings Call Highlights: Navigating Market Challenges with Strategic Expansions
Q1 2026 Alleima AB Earnings Call Transcript
Q1 2026 Alleima AB Earnings Call Transcript
Alleima AB Earnings Call Transcript: Q1 2026
Market uncertainty and Middle East instability led to lower order intake and revenues, but strong performance in medical, industrial heating, and Kanthal segments helped offset declines. Efficiency measures and a solid balance sheet support ongoing investments and resilience.
Alleima AB Earnings Call Transcript: Q4 2025
2025 saw flat organic revenue amid geopolitical and market headwinds, with strong performance in medical, nuclear, and oil & gas offset by weakness in industrial and chem/petrochem. Efficiency measures and capacity expansions are underway, and a strong balance sheet supports continued strategy execution.
Alleima AB Transcript: CMD 2025
Profitable growth is driven by targeted investments in high-return segments like medical, nuclear, and industrial heating, supported by strong financials and a resilient, diversified portfolio. Sustained R&D, operational excellence, and a focus on sustainability underpin future value creation.
Alleima AB Earnings Call Transcript: Q3 2025
Challenging market conditions persist, with flat revenues and a decline in adjusted EBIT margin due to weak demand in Europe and the Americas, FX headwinds, and a prolonged maintenance shutdown. Cost-saving and restructuring measures are underway, with strong backlogs in key segments and a robust financial position.
Alleima AB Earnings Call Transcript: Q2 2025
Organic revenues declined 4% year-over-year amid weak demand in Europe and North America, with adjusted EBIT margin at 9.5% and strong performance in oil & gas, nuclear, and medical segments. Q3 is expected to be seasonally weaker due to extended maintenance and continued FX headwinds.
Alleima AB Earnings Call Transcript: Q1 2025
Solid Q1 performance with 8% organic revenue growth and 10.5% adjusted EBIT margin, supported by strong backlog and diversified segment contributions. Guidance maintained for full-year CapEx and tax, with cautious outlook amid global uncertainty.
Alleima AB Earnings Call Transcript: Q4 2024
Organic revenue grew 1% for the year and 3% in Q4, with strong performance in oil and gas, nuclear, and medical segments, while industrial and Europe lagged. Adjusted EBIT margin was 11.5% in Q4, and the board proposed a 15% higher dividend. CapEx guidance for 2025 is SEK 1.2 billion.
Alleima AB Earnings Call Transcript: Q3 2024
Organic order intake declined 8% year-over-year, mainly due to oil and gas and industrial heating, while revenues grew 3% organically and adjusted EBIT margin reached 7% despite currency headwinds. Strategic investments in nuclear and medical capacity, strong cash flow, and a robust financial position support continued growth amid mixed market conditions.
Alleima AB Earnings Call Transcript: Q2 2024
Revenues were flat at SEK 5.4 billion with strong cash flow and resilient margins despite a 4% decline in order intake due to timing and high comparables. Market sentiment is improving, especially in industrial and consumer segments, while the company maintains a strong financial position and solid backlog.